NEWS4 April 2014
US — IMS Health has priced its initial public offering at $20 a share, which stands to generate $1.3bn for the company and its private equity owners.
The healthcare data firm is putting 52m shares up for sale, with the resulting proceeds – around $1bn – earmarked for paying down existing long-term debt.
Meanwhile, the investment firms that took IMS private in a $5bn deal in 2010 will sell 13m shares – returning $260m to their coffers.
IMS filed for an IPO in January this year. The offering is expected to close on 9 April. Shares are expected to begin trading on the New York Stock Exchange (NYSE) today under the ticker symbol IMS.
Pictured is IMS CEO Ari Bousbib.
UPDATE: IMS shares opened at $22.18 on the NYSE this morning. As of 10.15am ET they were trading at $22.85.
The world's leading job site for research and insight
Hasson Associates
Senior Reporting Analyst, Insights Media & Advertising
£35000–40000
Resources Group
Qualitative & Quantitative Researchers – International consultancy
$90,0000–$100,000 + superannuation + benefits
Resources Group
Research Director – Utilities, Transport, Energy
£50,000–£60,000
Featured company
-
Town/Country: Aylesbury
Tel: +44 (0)1296 632578
2Europe are an award-winning, full-service market research agency. We provide domestic and international research services to clients from all industries; particularly B2B, finance, healthcare and the built environment. We offer . . .
Related Articles
0 Comments